Moderna’s impressive portfolio leveraging cutting-edge innovation propels it as a noteworthy competitor to industry giants like Pfizer, Sanofi, AstraZeneca, and GSK.
From their groundbreaking COVID-19 vaccine to their recent RSV vaccine approval and outstanding data for the COVID-19+Flu combination vaccine, Moderna is setting new standards and pushing the boundaries of what’s possible in medicine.
‘Moderna’izing Health
Agility, innovation and creativity fuels Moderna’s strategic choices and makes us all wonder how they will leverage their competitive advantages in vaccines and beyond.
To learn more about Moderna’s vaccines portfolio, strategy and upcoming milestones, read the full report below.
Related Insights & Outlooks
Q3-2024 Top Pharma Earnings Results
•
November 18, 2024
From breakthrough therapies to strategic market maneuvers, here’s how the Top 15 Pharma Companies navigated the quarter’s challenges and opportunities.
Q2-2024 Top Pharma Earnings Results
•
August 14, 2024
The pharmaceutical industry showed impressive performance in Q2 2024, with a notable focus on innovation and expansion.
.avif)